Phillip Frost wants a bigger bite of the global drug market for Teva Pharmaceutical Industries, which is why the board chairman and other directors hired Jeremy Levin to be the next chief executive officer of the world's largest generic manufacturer.Levin leaves Bristol-Myers Squibb, where he helped engineer the company's "string-of-pearls strategy," in which it forged successful partnership and licensing agreements with other companies.In choosing a doctor with a scientific and dealmaking background, Frost said, the Teva board wants to profit more from its move into different areas, including more branded drugs and over-the-counter products through a marketing deal with Procter & Gamble, while squeezing more out of its long-held global lead in the generic-drug market.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac... -
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma... -
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th... -
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after... -
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y... -
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ... -
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment